Page last updated: 2024-08-25

rosiglitazone and Graft Occlusion, Vascular

rosiglitazone has been researched along with Graft Occlusion, Vascular in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Acampado, E; Cheng, Q; Davis, T; Eppihimer, M; Ezell, T; Finn, AV; Gold, HK; John, M; Karmali, V; Kolodgie, FD; Lajoie, S; Nakazawa, G; Polavarapu, R; Raghunathan, C; Virmani, R; Xu, X	1
Collins, AR; Fleck, E; Goetze, S; Hsueh, WA; Kaneshiro, K; Kim, S; Kintscher, U; Law, RE; Meehan, WP	1

Other Studies

2 other study(ies) available for rosiglitazone and Graft Occlusion, Vascular

Article	Year
Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. Circulation research, 2009, Nov-06, Volume: 105, Issue:10 Topics: Animals; Aorta; Cells, Cultured; Drug-Eluting Stents; Endothelial Cells; Graft Occlusion, Vascular; Heme Oxygenase-1; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Models, Biological; Paclitaxel; PPAR gamma; Protein Kinases; Proto-Oncogene Proteins c-akt; Rabbits; Rosiglitazone; Sirolimus; Thiazolidinediones; TOR Serine-Threonine Kinases; Tubulin Modulators	2009
Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. Journal of cardiovascular pharmacology, 2001, Volume: 38, Issue:6 Topics: Animals; Aortic Diseases; Cell Adhesion; Cell Movement; Cell Nucleus; Cells, Cultured; Chromans; Cytosol; Enzyme Inhibitors; Graft Occlusion, Vascular; Ligands; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone	2001

Article

Year

Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation.

Circulation research, 2009, Nov-06, Volume: 105, Issue:10

Topics: Animals; Aorta; Cells, Cultured; Drug-Eluting Stents; Endothelial Cells; Graft Occlusion, Vascular; Heme Oxygenase-1; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Models, Biological; Paclitaxel; PPAR gamma; Protein Kinases; Proto-Oncogene Proteins c-akt; Rabbits; Rosiglitazone; Sirolimus; Thiazolidinediones; TOR Serine-Threonine Kinases; Tubulin Modulators

2009

Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.

Journal of cardiovascular pharmacology, 2001, Volume: 38, Issue:6

Topics: Animals; Aortic Diseases; Cell Adhesion; Cell Movement; Cell Nucleus; Cells, Cultured; Chromans; Cytosol; Enzyme Inhibitors; Graft Occlusion, Vascular; Ligands; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone

2001